Fibroscan Shear Wave Elastography (SWE) at Dr. Essa Lab

Fibroscan Shear Wave Elastography (SWE) at Dr. Essa Lab

Fibroscan Shear Wave Elastography (SWE) is a state-of-the-art, non-invasive diagnostic imaging technique designed to assess liver health with high precision. This advanced modality combines traditional ultrasound technology with low-frequency shear waves to evaluate two critical aspects of liver pathology: hepatic stiffness (which correlates directly with liver fibrosis or scarring) and the Controlled Attenuation Parameter (CAP), which quantifies hepatic steatosis (fat accumulation). At Dr. Essa Lab, this modern diagnostic tool serves as a highly reliable, painless, and rapid alternative to traditional liver biopsies, which carry inherent risks such as bleeding, pain, and infection.

The technology operates on the principles of tissue elasticity. During a Fibroscan Shear Wave Elastography procedure, a specialized ultrasound transducer generates a mild, low-frequency acoustic wave (shear wave) that travels through the liver tissue. The velocity of this shear wave is tracked using high-frequency ultrasound pulses. Because shear waves travel faster through stiff, scarred tissues than through soft, healthy tissues, the system can calculate the precise elastic modulus of the liver parenchyma, expressed in kilopascals (kPa). Simultaneously, the attenuation of the ultrasound beam is measured to calculate the CAP score, expressed in decibels per meter (dB/m), providing a quantitative assessment of liver fat. This dual-action capability makes Fibroscan SWE an indispensable tool in the modern hepatology and gastroenterology landscape.

Evaluating the liver parenchyma with Fibroscan SWE is of paramount clinical importance. Chronic liver diseases often progress silently, with patients remaining asymptomatic for years while progressive fibrosis gradually compromises liver function, potentially leading to cirrhosis, portal hypertension, and hepatocellular carcinoma. By providing an accurate, reproducible, and quantitative baseline of liver stiffness and fat content, Fibroscan SWE allows clinicians at Dr. Essa Lab to detect early-stage liver damage, monitor disease progression, evaluate the efficacy of therapeutic interventions, and make informed clinical decisions without exposing the patient to the discomfort and risks of invasive surgical procedures.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of accuracy and prevent confounding variables from affecting the liver stiffness measurements, patients must adhere to specific preparation guidelines prior to undergoing Fibroscan Shear Wave Elastography (SWE) at Dr. Essa Lab:

• Complete Fasting: Patients must fast for a minimum of 3 to 4 hours prior to the procedure. This includes abstaining from all food, beverages, and water. Consuming food or liquids increases portal blood flow and hepatic congestion, which can artificially elevate liver stiffness measurements and lead to an inaccurate overestimation of fibrosis.
• Medication Management: Routine medications may be taken with a very small sip of water, unless otherwise directed by the referring physician. Patients should inform the clinical staff of all medications, supplements, and herbal remedies they are currently taking.
• Comfortable Attire: Patients are advised to wear loose, comfortable clothing that allows easy access to the right upper quadrant of the abdomen and the right lower rib cage. A two-piece outfit is highly recommended.
• Medical History Documentation: Patients should bring all relevant medical records, including previous liver function tests (LFTs), viral hepatitis serologies, abdominal ultrasounds, CT scans, or prior Fibroscan reports, to assist the interpreting radiologist.
• Avoid Strenuous Activity: It is recommended to avoid intense physical exercise or heavy lifting immediately before the test, as physical exertion can temporarily alter systemic and hepatic hemodynamics.

During the Procedure

The Fibroscan Shear Wave Elastography (SWE) procedure is designed to be quick, painless, and highly comfortable for the patient. The entire process typically takes between 10 and 15 minutes:

• Patient Positioning: The patient is asked to lie flat on their back (supine position) on the examination table. The right arm is fully extended and placed behind the head. This specific posture expands the intercostal spaces (the spaces between the ribs), providing the clinical operator with an unobstructed acoustic window to the right lobe of the liver.
• Application of Gel: A small amount of hypoallergenic, water-soluble ultrasound gel is applied to the skin over the right lower rib cage. This gel eliminates air pockets between the transducer probe and the skin, ensuring optimal transmission of the acoustic waves.
• Probe Placement and Measurement: The clinical operator places the specialized Fibroscan probe (typically an M-probe or XL-probe, selected based on the patient's body mass index) in the intercostal space over the liver. The operator then activates the system to deliver a series of painless acoustic pulses.
• Sensation and Experience: The patient will feel a mild, rapid flicking or tapping sensation on the skin surface at the site of the probe. This is entirely painless and represents the generation of the low-frequency shear wave. There is absolutely no radiation, heat, or deep pressure involved.
• Data Acquisition: The system requires a minimum of 10 valid measurements to generate a reliable median liver stiffness value (kPa) and a median CAP score (dB/m). The advanced software automatically calculates the success rate and the interquartile range (IQR) to ensure quality control and diagnostic reliability.
• Post-Procedure Care: Once the required measurements are successfully captured, the gel is wiped off, and the patient can immediately resume all normal daily activities, including driving, working, and eating. There is no recovery time or post-procedure monitoring required.

When is a Fibroscan Shear Wave Elastography (SWE) Performed?

Assessment of Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

Fibroscan Shear Wave Elastography is frequently indicated for individuals suspected of having Non-Alcoholic Fatty Liver Disease (NAFLD), recently reclassified as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). With the rising prevalence of obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome, early detection of hepatic steatosis and its progression to Metabolic Dysfunction-Associated Steatohepatitis (MASH) is crucial. Physicians request this test to quantify the percentage of fat accumulation in the liver and to determine if this fat has initiated inflammatory changes leading to early-stage liver fibrosis.

Monitoring Chronic Viral Hepatitis (Hepatitis B and C)

Patients diagnosed with chronic Hepatitis B or Hepatitis C require regular monitoring to assess the degree of liver injury caused by persistent viral replication. Fibroscan SWE is performed to stage liver fibrosis non-invasively at the time of diagnosis and at regular intervals during and after antiviral therapy. This helps clinicians evaluate whether the antiviral treatment is successfully halting or reversing liver scarring, thereby guiding long-term management strategies and determining the risk of long-term complications.

Evaluation of Alcoholic Liver Disease (ALD)

Chronic, excessive alcohol consumption can lead to a spectrum of liver injuries, ranging from simple steatosis to alcoholic hepatitis, progressive fibrosis, and ultimately cirrhosis. Fibroscan SWE is utilized to assess the severity of liver damage in patients with a history of alcohol abuse. By quantifying liver stiffness, healthcare providers can objectively demonstrate the extent of liver scarring to the patient, monitor the regenerative capacity of the liver upon cessation of alcohol intake, and implement appropriate therapeutic interventions.

Investigation of Unexplained Elevated Liver Enzymes

When routine blood tests reveal persistently elevated liver enzymes, such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP), without an obvious cause, a Fibroscan SWE is often indicated. This diagnostic test helps clinicians look beyond superficial blood markers to evaluate the structural integrity of the liver parenchyma. It assists in ruling out underlying progressive liver diseases, autoimmune hepatitis, or drug-induced liver injury (DILI) by providing immediate structural and elastic data.

Staging and Monitoring of Cirrhosis and Portal Hypertension Risk

For patients with known chronic liver disease, determining the transition from advanced fibrosis to established cirrhosis (F4) is critical for clinical prognosis. Fibroscan SWE is performed to identify cirrhosis non-invasively and to monitor patients for signs of portal hypertension. Extremely high liver stiffness values (typically exceeding 20 to 25 kPa) correlate strongly with the presence of clinically significant portal hypertension, allowing physicians to screen for esophageal varices and initiate preventive therapies to reduce the risk of variceal bleeding.

What Does a Fibroscan Shear Wave Elastography (SWE) Detect?

Fibroscan Shear Wave Elastography (SWE) is highly sensitive and specific, capable of detecting a wide array of pathological changes and clinical parameters within the liver parenchyma. The key findings and parameters detected by this advanced diagnostic modality include:

• Normal Liver Stiffness: Indicates healthy liver tissue with no significant fibrosis (typically ranging between 2.0 and 5.5 kPa).
• Mild Liver Fibrosis (F1): Detects early, localized scarring around the portal tracts without septae formation.
• Moderate Liver Fibrosis (F2): Identifies progressive scarring with few septae extending between portal areas.
• Severe Liver Fibrosis (F3): Detects bridging fibrosis with numerous septae connecting portal and central hepatic areas, indicating advanced structural damage.
• Hepatic Cirrhosis (F4): Identifies diffuse, irreversible scarring with regenerative nodule formation and severe architectural distortion.
• Normal Hepatic Fat Fraction (S0): Indicates minimal or no fat accumulation within the hepatocytes (CAP score below 238 dB/m).
• Mild Hepatic Steatosis (S1): Detects fat accumulation affecting less than 33% of hepatocytes (CAP score ranging from 238 to 260 dB/m).
• Moderate Hepatic Steatosis (S2): Identifies fat accumulation affecting 33% to 66% of hepatocytes (CAP score ranging from 261 to 290 dB/m).
• Severe Hepatic Steatosis (S3): Detects extensive fat accumulation affecting more than 66% of hepatocytes (CAP score exceeding 290 dB/m).
• Shear Wave Velocity (m/s): Measures the physical speed of the acoustic wave, where higher velocities directly correlate with increased tissue stiffness.
• Hepatic Inflammation Flares: Detects temporary, acute elevations in liver stiffness caused by active cellular inflammation, which must be clinically correlated with liver enzymes.
• Biliary Obstruction Effects: Identifies increased liver stiffness secondary to extrahepatic cholestasis or bile duct obstruction.
• Hepatic Congestion: Detects passive liver congestion and increased stiffness caused by right-sided heart failure or fluid overload.
• Treatment Response in Chronic Hepatitis: Demonstrates a decrease in liver stiffness over time, indicating successful therapeutic regression of fibrosis.
• Fatty Infiltration Patterns: Helps characterize whether hepatic steatosis is diffuse or focal when combined with standard B-mode ultrasound.
• Risk of Portal Hypertension: High kPa values indicate a elevated risk of portal venous system congestion and associated complications.
• Post-Transplant Graft Status: Monitors liver transplant recipients for early signs of graft rejection, recurrent disease, or biliary complications.
• Drug-Induced Liver Injury (DILI): Detects parenchymal changes and scarring resulting from hepatotoxic medications or herbal supplements.
• Autoimmune Hepatitis Progression: Monitors the chronic inflammatory and fibrotic impact of autoimmune-mediated liver damage.
• Hemochromatosis and Wilson's Disease Impact: Evaluates the structural damage and fibrosis resulting from abnormal iron or copper deposition in the liver.
• Alpha-1 Antitrypsin Deficiency Effects: Detects progressive liver scarring associated with genetic metabolic disorders.
• Primary Biliary Cholangitis (PBC) Staging: Evaluates the chronic destruction of small bile ducts and subsequent progressive portal fibrosis.
• Primary Sclerosing Cholangitis (PSC) Scarring: Assesses the fibrotic impact of chronic inflammation and narrowing of the intrahepatic and extrahepatic bile ducts.
• Quality Control Metrics (IQR/M): Evaluates the reliability of the exam by calculating the ratio of the interquartile range to the median stiffness value, ensuring clinical validity.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is dedicated to providing rapid, accurate, and highly accessible diagnostic reporting to facilitate timely clinical decisions. Because Fibroscan Shear Wave Elastography (SWE) relies on digital data acquisition and real-time software analysis, the preliminary quantitative measurements (kPa and CAP scores) are generated immediately upon completion of the scan. A consultant radiologist or specialized sonologist at Dr. Essa Lab then reviews the quantitative data, correlates it with the patient's clinical history, and compiles a comprehensive, structured diagnostic report.

The finalized Fibroscan SWE report is typically available within a few hours to a maximum of 24 hours after the procedure. Dr. Essa Lab offers multiple convenient methods for patients and referring physicians to access these reports. Patients can securely download their digital reports and high-resolution imaging findings through the official Dr. Essa Lab online portal or dedicated mobile application. Additionally, physical copies of the report can be collected directly from the main diagnostic center or any of the conveniently located collection points across Karachi and other major cities. This seamless integration of technology ensures that patients can share their results with their healthcare providers without unnecessary delays.

Fibroscan Shear Wave Elastography (SWE) Findings Overview

The following table provides a general clinical overview of the parameters evaluated during a Fibroscan Shear Wave Elastography (SWE) procedure, along with their corresponding normal and abnormal clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Liver Stiffness Measurement (LSM)	2.0 to 5.5 kPa (Indicates healthy, elastic liver parenchyma with no fibrosis)	> 7.0 kPa (Mild to moderate fibrosis); > 11.5 to 12.5 kPa (Severe fibrosis or established cirrhosis)
Controlled Attenuation Parameter (CAP)	< 238 dB/m (Indicates normal liver fat content, S0)	238 to 260 dB/m (Mild steatosis, S1); 261 to 290 dB/m (Moderate, S2); > 290 dB/m (Severe steatosis, S3)
Shear Wave Velocity (SWV)	< 1.4 meters per second (m/s)	> 1.6 to 2.0+ m/s (Indicates rapid wave propagation through stiff, non-compliant, or scarred tissue)
Interquartile Range / Median Ratio (IQR/M)	≤ 30% (Indicates high measurement reliability and low variability among samples)	> 30% (Indicates high variability, potentially reducing the clinical reliability of the median stiffness score)
Liver Parenchyma Visualization	Homogeneous echotexture, smooth liver surface, normal caliber of hepatic and portal veins	Coarse echotexture, nodular or irregular liver surface, attenuated hepatic veins, or dilated portal vein
Spleen Stiffness (if evaluated)	Normal splenic stiffness (typically < 20 kPa)	Elevated splenic stiffness (often > 30 kPa, correlating strongly with advanced portal hypertension)
Success Rate of Measurements	100% success rate (10 valid acquisitions out of 10 attempts)	< 60% success rate (often due to narrow intercostal spaces, severe ascites, or high body mass index)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Fibroscan Shear Wave Elastography (SWE)?

• Experienced Healthcare Professionals: Dr. Essa Lab boasts a team of highly qualified consultant radiologists, sonologists, and clinical technicians specializing in advanced hepatic imaging and non-invasive elastography.
• Patient-Focused Care: Every patient receives compassionate, individualized attention, ensuring a comfortable, stress-free, and dignified diagnostic experience from arrival to report collection.
• Quality Diagnostic Services: As a pioneer in the diagnostic sector since 1987, Dr. Essa Lab maintains rigorous quality control standards, ensuring clinical accuracy and reliability across all diagnostic modalities.
• Professional Reporting: Reports are structured, detailed, and include quantitative kPa and CAP values, providing clear, actionable data for hepatologists and gastroenterologists.
• Modern Diagnostic Approach: Dr. Essa Lab utilizes state-of-the-art Fibroscan and shear wave elastography systems equipped with advanced software to ensure precise tissue characterization.
• Comfortable Environment: Our diagnostic centers are designed with patient comfort in mind, featuring clean, hygienic, and modern scanning suites.
• Convenient Location: With an extensive network of branches and collection centers across Karachi and other major cities, accessing premium diagnostic services is convenient and hassle-free.
• Commitment to Accurate Diagnosis: Dr. Essa Lab is dedicated to delivering precise, evidence-based diagnostic insights, helping clinicians formulate optimal treatment plans for chronic liver diseases.